This variant was found in a large number of cases of myeloproliferative disorders: 71 of 73 patients with polycythaemia vera (97%), 29 of 51 with essential thombocythaemia (57%), and 8 of 16 with idiopathic myelofibrosis (50%). The mutation was detected in granulocytes, which are descended from a myeloid precursor. In 30 cases T-cells (instead descending from a lymphoid precursor) were tested and found not to carry the mutation, indicating this variant is always, or almost always, an acquired mutation and not inherited.
The mutation was not detected in 90 control samples (from a population with type I diabetes).
A variety of patients with myeloproliferative disorders were profiled, sorted by self-reported disease status. Out of 164 genotyped individual with polycythaemia vera 84% carried the variant — 26 did not have the mutation, 80 were heterozygous, and 41 homozygous (presumably due to loss of heterozygosity). Of 115 genotyped with essential thrombocythemia 32% carried the variant — 78 did not have the mutation, 34 were heterozygous, and 3 were homozygous. Of 46 with myeloid metaplasia with myelofibrosis 35% carried the variant — 30 did not have the mutation, 12 were heterozygous, and 4 were homozygous.
In addition, the study genotyped this position in 269 samples from a panel collected by the International HapMap Consortium, all were homozygous for the wild-type variant. However, many of these were trios, only 420 of the 540 chromosomes tested were independent (120 from Utah NW European, 120 from Nigeria Yoruban, 90 from Han Chinese, 90 from Japanese) — assuming the one failed test accounts for a single individual, this represents 418 unrelated chromosomes found to carry the wild-type variant (equivalent to 209 individuals).
Of 128 patients with polycythemia vera 65% carried the variant — 48 were heterozygous for the variant, and 35 were homozygous for it. Of 93 patients with essential thrombopenia 23% carried the variant — 18 were heterozygous for it, 3 homozygous. Of 23 patients with idiopathic myelofibrosis 57% carried the variant — 8 were heterozygous for it, 3 homozygous.
Of 71 healthy controls, none had this variant. This was also true for 9 patients with chronic myelogenous leukemia and 11 with secondary erythrocytosis.
Notably, the numbers reported here differ dramatically from those reported by Baxter et al. (71/2 carrier/non-carrier in Baxter et al. vs. 83/45 here, for PV cases). This may reflect differences in methods for disease diagnosis.